Rhenman & Partners Asset Management Ab Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Rhenman & Partners Asset Management Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$83.14 - $145.99 $11.3 Million - $19.9 Million	-136,000 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$110.08 - $142.92 $1.54 Million - $2 Million	-14,000 Reduced 9.33%	136,000 $16.1 Million
Q4 2021 Feb 11, 2022	BUY	$99.73 - $148.48 $1.5 Million - $2.23 Million	15,000 Added 11.11%	150,000 $20.7 Million
Q3 2021 Nov 12, 2021	SELL	$98.85 - $138.91 $6.47 Million - $9.09 Million	-65,419 Reduced 32.64%	135,000 $18.8 Million
Q1 2021 May 14, 2021	SELL	$64.07 - $91.75 $2.22 Million - $3.17 Million	-34,581 Reduced 14.72%	200,419 $13.7 Million
Q4 2020 Jan 19, 2021	SELL	$65.07 - $98.24 $4.88 Million - $7.37 Million	-75,000 Reduced 24.19%	235,000 $20.1 Million
Q3 2020 Oct 13, 2020	BUY	$59.04 - $77.95 $5.9 Million - $7.8 Million	100,000 Added 47.62%	310,000 $20.2 Million
Q2 2020 Jul 16, 2020	BUY	$29.01 - $74.23 $2.03 Million - $5.2 Million	70,000 Added 50.0%	210,000 $15.4 Million
Q1 2020 Apr 16, 2020	BUY	$27.51 - $57.29 $412,650 - $859,350	15,000 Added 12.0%	140,000 $4.76 Million
Q4 2019 Jan 17, 2020	BUY	$40.86 - $57.65 $5.11 Million - $7.21 Million	125,000 New	125,000 $6.81 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.